name: zinc finger protein 513 isoform h3 (human)

description: A zinc finger protein 513 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8N8E2-3.


cytochrome P450 3A7 isoform h1 (human)

A cytochrome P450 3A7 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P24462-1.


cytochrome P450 3A7 isoform h2 (human)

A cytochrome P450 3A7 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P24462-2.


name: serum paraoxonase/arylesterase 1 N-glycosylated 9 (human)

description: A serum paraoxonase/arylesterase 1 (human) that has been N-glycosylated at the residue equivalent to Asn-253 of the amino acid sequence represented by UniProtKB:P27169-1, in which the glycan composition is represented by GlyTouCan:G95865ZB. Example: UniProtKB:P27169-1, Asn-253, MOD:00160~GNO:G95865ZB.


name: Acrodysostosis 1 with or without hormone resistance

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: An autosomal dominant skeletal dysplasia caused by mutation(s) in the PRKAR1A gene, encoding cAMP-dependent protein kinase type I-alpha regulatory subunit. It is characterized by short stature, brachydactyly, and characteristic facial features. Resistance to multiple hormones is a common finding.


name: acrodysostosis 2 with or without hormone resistance

description: Any acrodysostosis in which the cause of the disease is a mutation in the PDE4D gene.


kallikrein-6 N-glycosylated 4 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G08146BT. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G08146BT.


kallikrein-6 isoform h3 (human)

A kallikrein-6 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q92876-3.


kallikrein-6 N-glycosylated 12 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G56069TX. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G56069TX.


kallikrein-6 N-glycosylated 13 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G57818FI. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G57818FI.


kallikrein-6 N-glycosylated 15 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G92534LG. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G92534LG.


kallikrein-6 N-glycosylated 11 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G53965RU. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G53965RU.


kallikrein-6 N-glycosylated 6 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G21327TO. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G21327TO.


kallikrein-6 N-glycosylated 3 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G07493GF. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G07493GF.


kallikrein-6 N-glycosylated 5 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G15828HX. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G15828HX.


kallikrein-6 N-glycosylated 8 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G28536BG. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G28536BG.


kallikrein-6 N-glycosylated 7 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G22208HN. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G22208HN.


kallikrein-6 N-glycosylated 1 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G01659NO. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G01659NO.


kallikrein-6 N-glycosylated 10 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G45495MK. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G45495MK.


kallikrein-6 N-glycosylated 9 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G44369QM. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G44369QM.


kallikrein-6 N-glycosylated 2 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G03081ER. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G03081ER.


kallikrein-6 isoform h1 (human)

A kallikrein-6 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q92876-1.


kallikrein-6 isoform h2 (human)

A kallikrein-6 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q92876-2.


kallikrein-6 N-glycosylated 14 (human)

A kallikrein-6 (human) that has been N-glycosylated at the residue equivalent to Asn-134 of the amino acid sequence represented by UniProtKB:Q92876-1, in which the glycan structure is represented by GlyTouCan:G68969GZ. Example: UniProtKB:Q92876-1, Asn-134, MOD:00160~GNO:G68969GZ.


name: DNA polymerase delta catalytic subunit phosphorylated 1 (human)

description: A DNA polymerase delta catalytic subunit (human) that has been phosphorylated on the residue at the position equivalent to Ser-928 of the amino acid sequence represented by UniProtKB:P28340. UniProtKB:P28340, Ser-928, MOD:00046.


name: poly(A) RNA polymerase, mitochondrial isoform h2 (human)

description: A poly(A) RNA polymerase, mitochondrial (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NVV4-2.


name: twist-related protein 2 isoform 1 (human)

description: A twist-related protein 2 isoform 1 that is encoded in the genome of human.


ethmoidal sinus neoplasm

description: A benign or malignant neoplasm that affects the ethmoid sinus. Representative examples of benign neoplasms include Schneiderian papilloma and salivary gland-type adenoma. Representative examples of malignant neoplasms include carcinoma and lymphoma.


benign neoplasm of sphenoidal sinus

description: A non-metastasizing neoplasm that arises from the sphenoid sinus.


sphenoidal sinus neoplasm

description: A benign or malignant neoplasm that affects the sphenoid sinus. Representative examples of benign neoplasms include Schneiderian papilloma and salivary gland-type adenoma. Representative examples of malignant neoplasms include carcinoma and lymphoma.


maxillary sinus neoplasm

description: A benign or malignant neoplasm that affects the maxillary sinus. Representative examples of benign neoplasms include Schneiderian papilloma and salivary gland-type adenoma. Representative examples of malignant neoplasms include carcinoma and lymphoma.


benign neoplasm of ethmoidal sinus

description: A benign neoplasm that involves the ethmoid sinus.


benign neoplasm of maxillary sinus

description: A benign neoplasm that involves the maxillary sinus.


ethmoid sinus ectopic meningioma

description: An extremely rare meningioma that arises as a primary ectopic tumor in the ethmoid sinus.


frontal sinus neoplasm

description: A benign or malignant neoplasm that affects the frontal sinus. Representative examples of benign neoplasms include Schneiderian papilloma and salivary gland-type adenoma. Representative examples of malignant neoplasms include carcinoma and lymphoma.


benign neoplasm of frontal sinus

description: A benign neoplasm that involves the frontal sinus.


name: LHFPL tetraspan subfamily member 3 protein

description: A protein that is a translation product of the human LHFPL3 gene or a 1:1 ortholog thereof.


name: StAR-related lipid transfer protein 9 phosphorylated 1 (human)

description: A StAR-related lipid transfer protein 9 (human) that has been phosphorylated on the residue at the position equivalent to Thr-3903 of the amino acid sequence represented by UniProtKB:Q9P2P6-1. Example: UniProtKB:Q9P2P6-1, Thr-3903, MOD:00047.


name: induced myeloid leukemia cell differentiation protein Mcl-1 isoform h1 (human)

description: An induced myeloid leukemia cell differentiation protein Mcl-1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q07820-1.


histone deacetylase 1 isoform 1 (human)

A histone deacetylase 1 isoform 1 that is encoded in the genome of human.


name: latent-transforming growth factor beta-binding protein 2 O-glycosylated 16 (human)

description: A latent-transforming growth factor beta-binding protein 2 (human) that has been O-glycosylated at the residue equivalent to Thr-278 of the amino acid sequence represented by UniProtKB:Q14767-1, in which the glycan composition is represented by GlyTouCan:G88713AC. Example: UniProtKB:Q14767-1, Thr-278, MOD:00005~GNO:G88713AC.


Carcinoid tumor of the duodenum

description: A well differentiated, low grade neuroendocrine neoplasm that arises from the duodenum. The mitotic count is less than 2 per 10 HPF and/or the Ki67 index is equal to or less than 2 percent.


N-(3-oxohexanoyl)-L-homoserine lactone

An N-acyl-L-homoserine lactone having 3-oxohexanoyl as the acyl substituent.


name: peroxisome proliferator-activated receptor gamma coactivator 1-alpha

description: A protein that is a translation product of the human PPARGC1A gene or a 1:1 ortholog thereof.


name: peroxisome proliferator-activated receptor gamma coactivator 1-alpha phosphorylated 1 (human)

description: A peroxisome proliferator-activated receptor gamma coactivator 1-alpha (human) that has been phosphorylated on the residue at the position equivalent to Thr-178, and phosphoserine at position 539 of the amino acid sequence represented by UniProtKB:Q9UBK2. UniProtKB:Q9UBK2, Thr-178, MOD:00047|Ser-539, MOD:00046.


name: peroxisome proliferator-activated receptor gamma coactivator 1-alpha isoform hB4-8a (human)

description: A peroxisome proliferator-activated receptor gamma coactivator 1-alpha (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UBK2-5.


name: peroxisome proliferator-activated receptor gamma coactivator 1-alpha isoform hB5 (human)

description: A peroxisome proliferator-activated receptor gamma coactivator 1-alpha (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UBK2-3.


name: peroxisome proliferator-activated receptor gamma coactivator 1-alpha isoform hB5-NT (human)

description: A peroxisome proliferator-activated receptor gamma coactivator 1-alpha (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UBK2-6.


name: peroxisome proliferator-activated receptor gamma coactivator 1-alpha isoform hB4-3ext (human)

description: A peroxisome proliferator-activated receptor gamma coactivator 1-alpha (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UBK2-7.


name: peroxisome proliferator-activated receptor gamma coactivator 1-alpha isoform hB4 (human)

description: A peroxisome proliferator-activated receptor gamma coactivator 1-alpha (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UBK2-4.


name: peroxisome proliferator-activated receptor gamma coactivator 1-alpha phosphorylated 2 (human)

description: A peroxisome proliferator-activated receptor gamma coactivator 1-alpha (human) that has been post-translationally modified to include phosphothreonine at positions 263 and 299, and phosphoserine at position 266 of the amino acid sequence represented by UniProtKB:Q9UBK2. UniProtKB:Q9UBK2, Thr-263/Thr-299, MOD:00047|Ser-266, MOD:00046.


name: peroxisome proliferator-activated receptor gamma coactivator 1-alpha sumoylated 1 (human)

description: A peroxisome proliferator-activated receptor gamma coactivator 1-alpha (human) that has been sumoylated on the residue at the position equivalent to Lys-184 of the amino acid sequence represented by UniProtKB:Q9UBK2-1. Example: UniProtKB:Q9UBK2-1, Lys-184, MOD:01149.


name: peroxisome proliferator-activated receptor gamma coactivator 1-alpha isoform h1 (human)

description: A peroxisome proliferator-activated receptor gamma coactivator 1-alpha (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UBK2-1.


name: peroxisome proliferator-activated receptor gamma coactivator 1-alpha isoform h8a (human)

description: A peroxisome proliferator-activated receptor gamma coactivator 1-alpha (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UBK2-8.


name: peroxisome proliferator-activated receptor gamma coactivator 1-alpha isoform h9 (human)

description: A peroxisome proliferator-activated receptor gamma coactivator 1-alpha (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UBK2-9.


name: peroxisome proliferator-activated receptor gamma coactivator 1-alpha isoform hNT-7a (human)

description: A peroxisome proliferator-activated receptor gamma coactivator 1-alpha (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UBK2-2.


activated factor Xa heavy chain (human)

An activated factor Xa heavy chain in human. UniProtKB:P00742, 235-488.


name: ribonuclease 8, signal peptide removed form (human)

description: A ribonuclease 8 (human) that has had the signal peptide removed. UniProtKB:Q8TDE3, 28-154.


adult germ cell tumor

description: A germ cell tumor that occurs during adulthood.


adult teratoma

description: A teratoma that occurs in an adult.


adult cystic teratoma

description: A cystic teratoma that occurs in an adult.


Paranasal Sinus Neuroendocrine Tumor G2

description: A well-differentiated, intermediate grade neuroendocrine neoplasm that arises from the paranasal sinuses.


name: elongation factor 1-delta isoform 3 (human)

description: An elongation factor 1-delta isoform 3 that is encoded in the genome of human.


name: Rap1 GTPase-activating protein 1 isoform h3 (human)

description: A Rap1 GTPase-activating protein 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P47736-3.


codanin-1 methylated 1 (human)

A codanin-1 (human) that has been methylated on the residue at the position equivalent to Cys-222 of the amino acid sequence represented by UniProtKB:Q8IWY9-2. Example: UniProtKB:Q8IWY9-2, Cys-222, MOD:00660.


name: thymidine phosphorylase isoform h2 (human)

description: A thymidine phosphorylase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P19971-2.


name: THO complex subunit 5 homolog isoform 1 (human)

description: A THO complex subunit 5 isoform 1 that is encoded in the genome of human.


name: THO complex subunit 5 homolog deaminated 1 (human)

description: A THO complex subunit 5 homolog (human) that has been deaminated on the residue at the position equivalent to Gln-141 of the amino acid sequence represented by UniProtKB:Q13769. UniProtKB:Q13769, Gln-141, MOD:00685.


name: THO complex subunit 5 homolog methylated 1 (human)

description: A THO complex subunit 5 homolog (human) that has been methylated on the residue at the position equivalent to Cys-630 of the amino acid sequence represented by UniProtKB:Q13769. UniProtKB:Q13769, Cys-630, MOD:00660.


name: THO complex subunit 5 homolog phosphorylated 1 (human)

description: A THO complex subunit 5 homolog (human) that has been phosphorylated at Tyr-225. UniProtKB:Q13769, Tyr-225, MOD:00048.


name: THO complex subunit 5 homolog, initiator methionine removed form (human)

description: A THO complex subunit 5 homolog (human) that has had the initiator methionine removed. UniProtKB:Q13769, 2-683.


name: THO complex subunit 5 homolog, initiator methionine removed phosphotyrosine form (human)

description: A THO complex subunit 5 homolog (human) that has had the initiator methionine removed and that includes at least 1 phosphorylated tyrosine. UniProtKB:Q13769, 2-683, MOD:00048.


name: CDK5 and ABL1 enzyme substrate 1 isoform h4 (human)

description: A CDK5 and ABL1 enzyme substrate 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8TDN4-4.


A 1-alkyl-sn-glycero-3-phosphocholine in which the alkyl group is specified as oleyl (9Z-octadecenyl).


name: dynein light chain Tctex-type protein 2B

description: A protein that is a translation product of the human DYNLT2B gene or a 1:1 ortholog thereof.


sphingomyelin d18:1/18:2

A sphingomyelin d18:1 in which the fatty acyl group contains 18 carbons and 2 double bonds.


name: serine/threonine-protein kinase N3 phosphorylated 1 (human)

description: A serine/threonine-protein kinase N3 (human) that has been phosphorylated on the residue at the position equivalent to Thr-718 of the amino acid sequence represented by UniProtKB:Q6P5Z2. UniProtKB:Q6P5Z2, Thr-718, MOD:00047.


A fatty acid ester resulting from the formal condensation of the hydroxy group at position-1 of glycerol with the carboxy group of erucic acid.


name: E3 ubiquitin-protein ligase RING1 isoform 1 (human)

description: An E3 ubiquitin-protein ligase RING1 isoform 1 that is encoded in the genome of human.


name: fructose-bisphosphate aldolase A deaminated 4 (human)

description: A fructose-bisphosphate aldolase A (human) that has been deaminated on the residue at the position equivalent to Asn-181 of the amino acid sequence represented by UniProtKB:P04075-1. Example: UniProtKB:P04075-1, Asn-181, MOD:00684.


name: pleckstrin homology domain-containing family G member 5 isoform h4 (human)

description: A pleckstrin homology domain-containing family G member 5 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O94827-7.


dapper homolog 2 isoform h2 (human)

A dapper homolog 2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q5SW24-2.


name: forkhead box protein O3, initiator methionine removed phosphorylated 1 (human)

description: A forkhead box protein O3 (human) that has had the initiator methionine removed and that has been phosphorylated on the residue at the position equivalent to Ser-215 of the amino acid sequence represented by UniProtKB:O43524-1. Example: UniProtKB:O43524-1, 2-673, Ser-215, MOD:00046.


name: kinesin-like protein KIF7 deaminated 1 (human)

description: A kinesin-like protein KIF7 (human) that has been deaminated on the residue at the position equivalent to Gln-487 of the amino acid sequence represented by UniProtKB:Q2M1P5. UniProtKB:Q2M1P5, Gln-487, MOD:00685.


name: iodotyrosine deiodinase 1 isoform h1 (human)

description: An iodotyrosine deiodinase 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q6PHW0-1.


name: volume-regulated anion channel subunit LRRC8C phosphorylated 1 (human)

description: A volume-regulated anion channel subunit LRRC8C (human) that has been phosphorylated on the residue at the position equivalent to Ser-543 of the amino acid sequence represented by UniProtKB:Q8TDW0. UniProtKB:Q8TDW0, Ser-543, MOD:00046.


name: volume-regulated anion channel subunit LRRC8C

description: A protein that is a translation product of the human LRRC8C gene or a 1:1 ortholog thereof.


name: volume-regulated anion channel subunit LRRC8C O-glycosylated 2 (human)

description: A volume-regulated anion channel subunit LRRC8C (human) that has been O-glycosylated at the residue equivalent to Thr-79 of the amino acid sequence represented by UniProtKB:Q8TDW0-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:Q8TDW0-1, Thr-79, MOD:00005~GNO:G43417UB.


name: volume-regulated anion channel subunit LRRC8C cysteinylated 1 (human)

description: A volume-regulated anion channel subunit LRRC8C (human) that has been cysteinylated on the residue at the position equivalent to Cys-599 of the amino acid sequence represented by UniProtKB:Q8TDW0. UniProtKB:Q8TDW0, Cys-599, MOD:00765.


name: volume-regulated anion channel subunit LRRC8C isoform 1 (human)

description: A volume-regulated anion channel subunit LRRC8C isoform 1 that is encoded in the genome of human.


name: volume-regulated anion channel subunit LRRC8C deaminated 3 (human)

description: A volume-regulated anion channel subunit LRRC8C (human) that has been deaminated on the residue at the position equivalent to Asn-70 of the amino acid sequence represented by UniProtKB:Q8TDW0. UniProtKB:Q8TDW0, Asn-70, MOD:00684.


name: volume-regulated anion channel subunit LRRC8C deaminated 1 (human)

description: A volume-regulated anion channel subunit LRRC8C (human) that has been deaminated on the residue at the position equivalent to Asn-468 of the amino acid sequence represented by UniProtKB:Q8TDW0. UniProtKB:Q8TDW0, Asn-468, MOD:00684.


name: volume-regulated anion channel subunit LRRC8C O-glycosylated 1 (human)

description: A volume-regulated anion channel subunit LRRC8C (human) that has been O-glycosylated at the residue equivalent to Ser-87 of the amino acid sequence represented by UniProtKB:Q8TDW0-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:Q8TDW0-1, Ser-87, MOD:00002~GNO:G43417UB.


name: volume-regulated anion channel subunit LRRC8C deaminated 2 (human)

description: A volume-regulated anion channel subunit LRRC8C (human) that has been deaminated on the residue at the position equivalent to Gln-709 of the amino acid sequence represented by UniProtKB:Q8TDW0. UniProtKB:Q8TDW0, Gln-709, MOD:00685.


name: laminin subunit alpha-5 deaminated 1 (human)

description: A laminin subunit alpha-5 (human) that has been deaminated on the residue at the position equivalent to Gln-2253 of the amino acid sequence represented by UniProtKB:O15230-1. Example: UniProtKB:O15230-1, Gln-2253, MOD:00685.


endrin

An organochlorine compound resulting from the epoxidation of the double bond of isodrin. It is the endo, endo stereoisomer of dieldrin. It is an insecticide mainly used on field crops such as cotton and grains and has also been used as a rodenticide to control mice and voles. The product is banned in many countries since it is a persistent organic pollutant.


name: facioscapulohumeral muscular dystrophy 1

description: Any facioscapulohumeral muscular dystrophy in which the cause of the disease is a mutation in the FRG1 gene.


name: tumor necrosis factor receptor superfamily member 12A

description: A protein that is a translation product of the human TNFRSF12A gene or a 1:1 ortholog thereof.


name: tumor necrosis factor receptor superfamily member 12A isoform h1 (human)

description: A tumor necrosis factor receptor superfamily member 12A (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NP84-1.


name: tumor necrosis factor receptor superfamily member 12A, signal peptide removed form (human)

description: A tumor necrosis factor receptor superfamily member 12A (human) that has had the signal peptide removed. UniProtKB:Q9NP84, 28-129.


name: tumor necrosis factor receptor superfamily member 12A isoform h2 (human)

description: A tumor necrosis factor receptor superfamily member 12A (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NP84-2.


Preterm Birth Complication

description: A complication related to a premature birth that occurs to a baby born prior to 37 weeks gestation.


vimentin deaminated 5 (human)

A vimentin (human) that has been deaminated on the residue at the position equivalent to Gln-228 of the amino acid sequence represented by UniProtKB:P08670. UniProtKB:P08670, Gln-228, MOD:00685.


Gollop-Wolfgang complex

description: Gollop-Wolfgang complex is a very rare malformation characterized by ectrodactyly of the hand and ipsilateral bifurcation of the femur.


RAD51-associated protein 2

A protein that is a translation product of the human RAD51AP2 gene or a 1:1 ortholog thereof.


name: cleavage and polyadenylation specificity factor subunit 6 isoform h2 (human)

description: A cleavage and polyadenylation specificity factor subunit 6 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q16630-2.


myricitrin-5-methyl ether

A monomethoxyflavone that is the 5-methyl ether derivative of myricitrin. Isolated from Rhododendron yedoense var poukhanense, it exhibits antioxidant activity.


integrin alpha-X deaminated 3 (human)

An integrin alpha-X (human) that has been deaminated on the residue at the position equivalent to Gln-570 of the amino acid sequence represented by UniProtKB:P20702. UniProtKB:P20702, Gln-570, MOD:00685.


Metastatic Salivary Duct Carcinoma

description: Salivary duct carcinoma that has spread from its original site of growth to another anatomic site.


Recurrent Salivary Duct Carcinoma

description: The reemergence of salivary duct carcinoma after a period of remission.


name: DNA-dependent metalloprotease SPRTN isoform h1 (human)

description: A DNA-dependent metalloprotease SPRTN (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9H040-1.


DNA-dependent metalloprotease SPRTN

A protein that is a translation product of the human SPRTN gene or a 1:1 ortholog thereof.


name: DNA-dependent metalloprotease SPRTN isoform h2 (human)

description: A DNA-dependent metalloprotease SPRTN (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9H040-2.


name: DNA-dependent metalloprotease SPRTN isoform h3 (human)

description: A DNA-dependent metalloprotease SPRTN (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9H040-3.


name: sulfite oxidase, mitochondrial, transit peptide removed form (human)

description: A sulfite oxidase, mitochondrial (human) that has had the transit peptide removed. UniProtKB:P51687, 80-545.


name: signal transducer and activator of transcription 6 methylated 1 (human)

description: A signal transducer and activator of transcription 6 (human) that has been methylated on the residue at the position equivalent to Cys-384 of the amino acid sequence represented by UniProtKB:P42226-1. Example: UniProtKB:P42226-1, Cys-384, MOD:00660.


name: tissue-type plasminogen activator N-glycosylated 16 (human)

description: A tissue-type plasminogen activator (human) that has been N-glycosylated at the residue equivalent to Asn-152 of the amino acid sequence represented by UniProtKB:P00750-1, in which the glycan structure is represented by GlyTouCan:G77038WW. Example: UniProtKB:P00750-1, Asn-152, MOD:00160~GNO:G77038WW.


name: peroxisomal membrane protein 11C isoform h2 (human)

description: A peroxisomal membrane protein 11C (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q96HA9-2.


name: Stage I Rectal Neuroendocrine Tumor AJCC v8

description: Stage I includes: T1, N0, M0. T1: Tumor invading the lamina propria or submucosa and measuring 2 cm or less. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)


name: tumor necrosis factor ligand superfamily member 15 isoform 2 (human)

description: A tumor necrosis factor ligand superfamily member 15 isoform 2 that is encoded in the genome of human.


name: Ral guanine nucleotide dissociation stimulator-like 1 isoform B (human)

description: A Ral guanine nucleotide dissociation stimulator-like 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NZL6-2.


name: Ral guanine nucleotide dissociation stimulator-like 1 isoform A (human)

description: A Ral guanine nucleotide dissociation stimulator-like 1 isoform 1 that is encoded in the genome of human.


name: extracellular matrix organizing protein FRAS1 isoform h5 (human)

description: An extracellular matrix organizing protein FRAS1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q86XX4-5.


name: BRISC complex subunit Abraxas 2 isoform 1 (human)

description: A BRISC complex subunit Abraxas 2 isoform 1 that is encoded in the genome of human.


ski-like protein isoform SNOA (human)

A ski-like protein (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P12757-2.


CIC-DUX4 Sarcoma

description: An undifferentiated, high grade small round cell sarcoma affecting predominantly young adults. It is characterized by a recurrent translocation involving the CIC gene on chromosome 19 and DUX4 gene on chromosome 4. The translocation results in CIC-DUX4, t(4;19)(q35;q13) fusions.


name: HAUS augmin-like complex subunit 7 isoform h1 (human)

description: A HAUS augmin-like complex subunit 7 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q99871-1.


Senile dementia

description: Loss of intellectual abilities in an elderly person, interfering with this person's activities.


name: mast/stem cell growth factor receptor Kit sequence variant V560G, signal peptide removed form (human)

description: A mast/stem cell growth factor receptor Kit (human) that has a Gly residue at the position equivalent to Val-560 of the amino acid sequence represented by UniProtKB:P10721-1 and that has had the signal peptide removed. Example: UniProtKB:P10721-1, 26-976, Val-560, CHEBI:29947.


lipase member M

A protein that is a translation product of the human LIPM gene or a 1:1 ortholog thereof.


name: lipase member M, signal peptide removed form (human)

description: A lipase member M (human) that has had the signal peptide removed. UniProtKB:Q5VYY2, 34-423.


lipase member M isoform h2 (human)

A lipase member M (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q5VYY2-2.


name: lipase member M phosphorylated 1 (human)

description: A lipase member M (human) that has been phosphorylated on the residue at the position equivalent to Ser-138 of the amino acid sequence represented by UniProtKB:Q5VYY2-1. Example: UniProtKB:Q5VYY2-1, Ser-138, MOD:00046.


lipase member M isoform h1 (human)

A lipase member M (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q5VYY2-1.


lipase member M deaminated 1 (human)

A lipase member M (human) that has been deaminated on the residue at the position equivalent to Gln-84 of the amino acid sequence represented by UniProtKB:Q5VYY2-1. Example: UniProtKB:Q5VYY2-1, Gln-84, MOD:00685.


name: interleukin-17 receptor E, signal peptide removed form (human)

description: An interleukin-17 receptor E (human) that has had the signal peptide removed. UniProtKB:Q8NFR9, 24-667.


aminodiol

An amino alcohol having two hydroxy functional groups.


N-lauryldiethanolamine

An aminodiol that is dodecylamine in which the amino hydrogens are replaced by 2-hydroxyethyl groups.


A 2-aminooctadecene-1,3-diol having its double bond at position 4.


An aminodiol composed of any octadecene having hydroxy functional groups at positions 1 and 3 and an amino substituent at position 2.


sphingenine

A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.


N-ethyldiethanolamine

A aminodiol that is diethanolamine in which the amino hydrogen has been replaced by an ethyl group. It is a metabolite of nitrogen mustards.


A sphingenine in which the C=C double bond is located at the 4-position.


An aminodiol that is octadecane bearing two hydroxy substituents at positions 1 and 3 as well as an amino substituent at position 2.


DIISOPROPANOLAMINE

A secondary amino compound that is diethanolamine substituted by methyl groups at positions 1 and 1'. It is a versatile chemical used in a variety of personal care, cosmetic and industrial products.


name: cell surface glycoprotein CD200 receptor 1, signal peptide removed form (human)

description: A cell surface glycoprotein CD200 receptor 1 (human) that has had the signal peptide removed. Example: UniProtKB:Q8TD46-1, 29-325.


name: corrinoid adenosyltransferase MMAB sequence variant R186W, transit peptide removed form (human)

description: A corrinoid adenosyltransferase MMAB (human) that has a Trp residue at the position equivalent to Arg-186 of the amino acid sequence represented by UniProtKB:Q96EY8 and that has had the transit peptide removed. UniProtKB:Q96EY8, 33-250, Arg-186, CHEBI:29954.


corrinoid adenosyltransferase MMAB

A protein that is a translation product of the human MMAB gene or a 1:1 ortholog thereof.


name: corrinoid adenosyltransferase MMAB sequence variant R191W, transit peptide removed form (human)

description: A corrinoid adenosyltransferase MMAB (human) that has a Trp residue at the position equivalent to Arg-191 of the amino acid sequence represented by UniProtKB:Q96EY8 and that has had the transit peptide removed. UniProtKB:Q96EY8, 33-250, Arg-191, CHEBI:29954.


name: corrinoid adenosyltransferase MMAB sequence variant E193L, transit peptide removed form (human)

description: A corrinoid adenosyltransferase MMAB (human) that has a Leu residue at the position equivalent to Glu-193 of the amino acid sequence represented by UniProtKB:Q96EY8 and that has had the transit peptide removed. UniProtKB:Q96EY8, 33-250, Glu-193, CHEBI:30006.


name: corrinoid adenosyltransferase MMAB, transit peptide removed form (human)

description: A corrinoid adenosyltransferase MMAB (human) that has had the transit peptide removed. UniProtKB:Q96EY8, 33-250.


name: 5-hydroxytryptamine receptor 2A isoform h2 (human)

description: A 5-hydroxytryptamine receptor 2A (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P28223-2.


name: intrapelvic lymph node leukemic reticuloendotheliosis


name: pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma

description: A recently recognized variant of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) that lacks somatic hypermutations of the Immunoglobulin heavy chain (IGH) genes, implying pregerminal center B-cell origin. Microarray gene expression profiling studies have demonstrated the expression of ZAP-70 gene (Syk family tyrosine kinase) in this subset of CLL/CLL. Patients with this variant of CLL/SLL have an unfavorable prognosis compared to those with somatic hypermutations of the IGH genes, with a median survival of approximately 6-8 years.


name: chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation

description: A recently recognized variant of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) expressing somatic hypermutations of the Immunoglobulin heavy chain (IGH) genes. The recognition of this variant alters the belief that CLL/SLL is always derived from a naive, pregerminal center B-cell. The presence of somatic hypermutations of IGH genes occurs in approximately 50% of CLL/SLL cases and implies a postgerminal center, memory origin. Patients with this variant of CLL/SLL have a favorable prognosis, with a reported median survival of more than 24 years.


name: protein turtle homolog A isoform h2 (human)

description: A protein turtle homolog A (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9P2J2-2.


name: protein turtle homolog A isoform 1 (human)

description: A protein turtle homolog A isoform 1 that is encoded in the genome of human.


name: SNW domain-containing protein 1, initiator methionine removed form (human)

description: A SNW domain-containing protein 1 (human) that has had the initiator methionine removed. UniProtKB:Q13573, 2-536.


name: Ras-related protein Rab-24 isoform 1 (human)

description: A Ras-related protein Rab-24 isoform 1 that is encoded in the genome of human.


haptoglobin N-glycosylated 8 (human)

A haptoglobin (human) that has been N-glycosylated at the residue equivalent to Asn-184 of the amino acid sequence represented by UniProtKB:P00738-1, in which the glycan structure is represented by GlyTouCan:G31118FR. Example: UniProtKB:P00738-1, Asn-184, MOD:00160~GNO:G31118FR.


name: partner and localizer of BRCA2 sequence variant W1140G (human)

description: A partner and localizer of BRCA2 (human) that has a Gly residue at the position equivalent to Trp-1140 of the amino acid sequence represented by UniProtKB:Q86YC2. UniProtKB:Q86YC2, Trp-1140, CHEBI:29947.


name: transcriptional enhancer factor TEF-5, initiator methionine removed form (human)

description: A transcriptional enhancer factor TEF-5 (human) that has had the initiator methionine removed. UniProtKB:Q99594, 2-435.


name: Breast Classic Lobular Carcinoma In Situ Type B

description: Breast classic lobular carcinoma in situ  characterized by the presence of neoplastic cells with nuclei of various sizes and shapes.


name: Early Stage HER2-Negative Breast Carcinoma

description: A HER2-negative breast adenocarcinoma that has not spread beyond the breast and the axillary lymph nodes.


name: Prognostic Stage IIIA Breast Cancer AJCC v8

description: Stage IIIA includes: (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); ( T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Breast Ductal Carcinoma In Situ and Invasive Lobular Carcinoma

description: A breast carcinoma characterized by the presence of a ductal carcinoma in situ component and an invasive lobular carcinomatous component.


Localized Breast Carcinoma

description: Breast carcinoma that is confined to the site in which it initially manifested without evidence of spread to other anatomic sites.


Invasive Breast Cribriform Carcinoma

description: An invasive adenocarcinoma of the breast with a favorable clinical outcome, characterized by the presence of a sieve-like or cribriform infiltrating pattern.


name: Intraductal Micropapillary Breast Carcinoma

description: Breast ductal carcinoma in situ characterized by the presence of neoplastic epithelial cells arranged in micropapillary patterns.


name: Solid papillary carcinoma in situ of breast

description: Breast solid papillary carcinoma characterized by the presence of nodules with rounded, well-circumscribed contours and a distribution pattern consistent with an in situ process. (WHO 2019)


Stage IIA Breast Carcinoma

description: Stage IIA includes: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 6th and 7th Eds.)


Stage IIIC Breast Cancer AJCC v7

description: Stage IIIC includes: Any T, N3, M0.  N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


name: Recurrent Hormone Receptor-Negative Breast Carcinoma

description: The reemergence of hormone receptor-negative breast carcinoma after a period of remission.


name: Invasive Breast Lobular Carcinoma, Solid Variant

description: A grade I invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells that form trabeculae and groups infiltrating collagen bundles.


name: Metastatic Triple-Negative Breast Carcinoma

description: A triple-negative breast carcinoma that has spread from its original site of growth to another anatomic site.


name: Invasive Breast Lobular Carcinoma with Predominant In Situ Component

description: A breast carcinoma characterized by the presence of a predominant lobular carcinoma in situ component and a minor component of invasive carcinoma.


Recurrent Malignant Breast Neoplasm

description: The reemergence of a malignant breast neoplasm after a period of remission.


name: Invasive Breast Lobular Carcinoma, Alveolar Variant

description: A grade I invasive lobular carcinoma of the breast, characterized by the presence of round groups of neoplastic cells.


Hereditary Female Breast Carcinoma

description: Breast carcinoma that has developed in female relatives of patients with history of breast carcinoma.


name: High Grade Ductal Breast Carcinoma In Situ

description: Breast ductal carcinoma in situ characterized by the presence of neoplastic cells with severe dysplasia and the formation of micropapillary, cribriform, or solid patterns. The nuclei show marked pleomorphism and have prominent nucleoli. Mitotic activity is usually present. There is comedo-type of necrosis present in the ducts. The necrotic debris is surrounded by pleomorphic malignant cells.


name: Breast Carcinoma Metastatic in the Liver

description: A carcinoma that originates from the breast and has spread to the liver.


name: Unresectable HER2-Negative Breast Carcinoma

description: A HER2-negative breast adenocarcinoma that is not amenable to surgical resection.


Recurrent Breast Mucinous Carcinoma

description: The reemergence of breast mucinous carcinoma after a period of remission.


Histiocytoid Breast Carcinoma

description: A rare variant of invasive lobular breast carcinoma characterized by the presence of histiocyte-like malignant cells with pale cytoplasm forming sheets or linear patterns. Apocrine differentiation may be present. It usually has an aggressive clinical course.


name: Squamous Cell Carcinoma In Situ of the Nipple

description: An intraepidermal squamous cell carcinoma involving the area of the nipple.


malignant neoplasm of breast stage I

description: Stage I includes: IA: T1, N0, M0 and IB: (T0, N1mi, M0); (T1, N1mi, M0).  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  T0: No evidence of primary tumor.  N0: No regional lymph node metastasis.  N1mi: Nodal micrometastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


name: Prognostic Stage 0 Breast Cancer AJCC v8

description: Stage 0 includes: Tis, N0, M0, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Locally Recurrent Breast Carcinoma

description: The reemergence of breast carcinoma after a period of remission, at or adjacent to the site of the original tumor.


name: Refractory HER2-Positive Breast Carcinoma

description: HER2-positive breast carcinoma that is resistant to treatment.


name: Invasive Breast Solid Papillary Carcinoma

description: Breast solid papillary carcinoma associated with areas featuring strands or large clusters of tumor cells. (WHO 2019)


Breast Florid Lobular Carcinoma In Situ

description: Breast lobular carcinoma in situ characterized by the presence of neoplastic cells with cytological features identical to classic lobular carcinoma in situ, but with marked distention of terminal ductal lobular units or ducts.


name: adenocarcinoma of breast with neuroendocrine differentiation

description: An invasive breast carcinoma characterized by the presence of focal neuroendocrine differentiation.


name: Metastatic Breast Inflammatory Carcinoma

description: Inflammatory carcinoma of the breast that has spread from its original site of growth to another anatomic site.


name: Metastatic Breast Neuroendocrine Tumor G1

description: A well differentiated neuroendocrine tumor that arises from the breast and has metastasized to other anatomic sites.


Stage IV Breast Cancer AJCC v6 and v7

description: Stage IV includes: Any T, Any N, M1.  M1: Distant metastasis. (AJCC 6th and 7th Eds.)


name: Unresectable Hormone Receptor-Negative Breast Carcinoma

description: Hormone receptor-negative breast carcinoma that is not amenable to surgical resection.


name: Breast Classic Lobular Carcinoma In Situ

description: Breast lobular carcinoma in situ characterized by the presence of dyscohesive proliferations of type A and/or type B epithelial cells. Type A cells are small cells with uniform hyperchromatic nuclei, whereas type B cells have slightly larger vesicular nuclei, with mild variability in size and shape and with small nucleoli. The cell populations may be mixed in individual proliferations. (WHO 2019)


Atypical Medullary Breast Carcinoma

description: An invasive ductal breast carcinoma characterized by the presence of a predominantly syncytial architectural pattern. It may have some, but not all the strictly defined additional morphologic criteria which are necessary for the diagnosis of medullary breast carcinoma (presence of a diffuse lymphoplasmacytic infiltrate, neoplastic round cells with abundant cytoplasm and vesicular nuclei, complete histological circumscription, and absence of glandular or tubular structures). It does not have the relatively favorable outcome that characterizes medullary breast carcinoma.


name: Refractory Hormone Receptor-Negative Breast Carcinoma

description: Hormone receptor-negative breast carcinoma that is resistant to treatment.


Breast Periductal Stromal Tumor

description: A rare, low-grade malignant stromal tumor that arises from the breast. It is characterized by the proliferation of atypical stromal spindle cells that surround benign tubules and ducts in a pericanalicular pattern. Mitotic activity is present. The tumor has a multinodular and infiltrative growth pattern and lacks the leaf-like architecture of phyllodes tumor. Wide excision with negative margins is the treatment of choice.


Primary angiosarcoma of breast

description: An angiosarcoma that arises from the breast parenchyma and is not associated with radiation exposure.


name: Metastatic HER2-Negative Breast Carcinoma

description: A HER2-negative breast adenocarcinoma that has spread to another anatomic site.


name: Recurrent HER2-Positive Breast Carcinoma

description: The reemergence of HER2-positive breast carcinoma after a period of remission.


Anatomic Stage 0 Breast Cancer AJCC v8

description: Stage 0 includes: Tis, N0, M0. Tis: Ductal carcinoma in situ. Lobular carcinoma in situ is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th Edition. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Stage IIIC Breast Cancer AJCC v6

description: Stage IIIC Breast Cancer was added in the 6th Edition AJCC Staging Manual, on the basis of metastasis to the infraclavicular lymph nodes (N3) plus any T, M0.


name: Hormone Receptor-Positive Breast Carcinoma

description: Breast adenocarcinoma that is positive for hormone receptors.


name: Refractory Hormone Receptor-Positive Breast Carcinoma

description: Hormone receptor-positive breast adenocarcinoma that does not respond to treatment.


Malignant nipple neoplasm male

description: A malignant neoplasm that affects the area of the nipple in males.


name: Metastatic Breast Neuroendocrine Neoplasm

description: A neuroendocrine neoplasm that arises from the breast and has metastasized to another anatomic site.


name: Inflammatory carcinoma of breast stage III

description: Inflammatory breast carcinoma is classified as AJCC Stage IIIB (T4d) unless other criteria indicate more advanced staging.


name: High Grade Breast Mucoepidermoid Carcinoma

description: An aggressive mucoepidermoid carcinoma that arises from the breast. It is characterized by the presence of focal necrosis and high mitotic activity. Lymph node and distant metastases are common. The prognosis is usually poor.


Postradiation Breast Angiosarcoma

description: A malignant vascular neoplasm arising from the skin of the breast secondary to radiation treatment for breast cancer.


name: Progesterone Receptor-Positive Breast Carcinoma

description: Breast adenocarcinoma that is positive for progesterone receptors.


name: Invasive Breast Ductal Carcinoma and Invasive Lobular Carcinoma

description: An invasive ductal breast carcinoma associated with an invasive lobular carcinomatous component.


name: Metastatic Estrogen Receptor-Positive Breast Carcinoma

description: Estrogen receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


Multicentric Breast Carcinoma

description: A breast carcinoma characterized by the presence of multiple cancerous tumors that originate from different clones and are usually located in different quadrants of the breast.


name: Breast Cancer by AJCC v8 Prognostic Stage

description: A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should be used in countries where HER2, ER, and PR biomarker tests are routinely performed for patient care (U.S., Canada, etc.). (from AJCC 8th Ed.)


Stage IIIB Breast Carcinoma

description: Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0).  T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules).  N0: No regional lymph node metastasis.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


name: Locally Advanced HER2-Negative Breast Carcinoma

description: A HER2-negative breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Prognostic Stage IIB Breast Cancer AJCC v8

description: Stage IIB includes: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Invasive Male Breast Carcinoma

description: A rare invasive carcinoma that arises from the male breast. Morphologically, it is similar to the invasive carcinomas that arise from the female breast. It usually develops in the retroareolar region.


Anatomic Stage II Breast Cancer AJCC v8

description: Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0); IIB: (T2, N1, M0); (T3, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Low Grade Breast Adenosquamous Carcinoma

description: A low grade metaplastic carcinoma of the breast with morphologic features similar to the adenosquamous carcinoma of the skin.  In the majority of cases the prognosis is excellent.


name: Refractory Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that is resistant to treatment.


name: Noninfiltrating intraductal papillary adenocarcinoma (morphologic abnormality)

description: Breast ductal carcinoma in situ characterized by the presence of filiform arborizing fibrovascular cores lined by neoplastic ductal epithelium. (WHO 2019)


HER2-Low Breast Carcinoma

description: A breast adenocarcinoma defined by low expression of HER2 (IHC1+ or IHC2+; FISH negative).


name: Metastatic Breast Signet Ring Cell Carcinoma

description: A signet ring cell carcinoma that arises from the breast and has metastasized to other anatomic sites.


Breast adenocarcinoma metastatic

description: An adenocarcinoma that arises from the breast and has metastasized to another anatomic site.


name: Recurrent Estrogen Receptor-Positive Breast Carcinoma

description: The reemergence of estrogen receptor-positive breast carcinoma after a period of remission.


Stage II Breast Cancer AJCC v6 and v7

description: Stage II includes: IIA: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0) and IIB: (T2, N1, M0); (T3, N0, M0).  T0: No evidence of primary tumor.  T1: Tumor 2.0 cm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension. T2: Tumor more than 2.0 cm but not more than 5.0 cm in greatest dimension.  T3: Tumor more than 5.0 cm in greatest dimension.  N1: Metastasis to movable ipsilateral axillary lymph node(s).  M0: No distant metastasis.  (AJCC 6th and 7th Eds.)


name: Inflammatory carcinoma of breast recurrent

description: The reemergence of inflammatory carcinoma of the breast after a period of remission


name: Breast Carcinoma with Choriocarcinomatous Features

description: An invasive ductal breast carcinoma, not otherwise specified, characterized by increased levels of human beta-chorionic gonadotropin in the serum.  Morphologic evidence of choriocarcinomatous differentiation is rare.


name: Prognostic Stage II Breast Cancer AJCC v8

description: Stage II includes: IIA: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIB: (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Carcinoma in situ of female breast

description: A proliferation of atypical neoplastic epithelial cells confined to the mammary ducts of the female breast.


name: Intraductal papillary adenocarcinoma with invasion

description: A carcinoma that has papillary growth and invades the wall and/or the surrounding tissues of the organ it originates from.


Recurrent Breast Angiosarcoma

description: The reemergence of breast angiosarcoma after a period of remission.


name: Anatomic Stage IIA Breast Cancer AJCC v8

description: Stage IIA includes: (T0, N1, M0); (T1, N1, M0); (T2, N0, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Malignant neoplasm of nipple of female breast

description: A malignant neoplasm that affects the area of the nipple in females.


name: Paget's disease and infiltrating duct carcinoma of breast

description: Paget disease involving the skin overlying the mammary gland, accompanied by invasive ductal breast carcinoma.


Anatomic Stage IA Breast Cancer AJCC v8

description: Stage IA includes: T1, N0, M0. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Recurrent Breast Medullary Carcinoma

description: The reemergence of breast medullary carcinoma after a period of remission.


name: Invasive Breast Lobular Carcinoma, Tubulolobular Variant

description: An invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells forming small tubular structures.


name: Hormone Receptor-Negative Breast Carcinoma

description: Breast adenocarcinoma that is negative for hormone receptors.


name: Locally Advanced Estrogen Receptor-Positive Breast Carcinoma

description: Estrogen receptor-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Breast sarcoma recurrent

description: The reemergence of breast sarcoma after a period of remission.


name: Breast Carcinoma with Osseous Metaplasia

description: An invasive breast carcinoma showing differentiation towards bone structures.


Breast Polymorphous Adenocarcinoma

description: A rare, low grade malignant epithelial neoplasm arising from the breast. It is characterized by the presence of uniform, small to medium size malignant epithelial cells and an infiltrating pattern.


Stage III Breast Cancer AJCC v7

description: Stage III includes: IIIA : (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0), IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0), and IIIC: (any T, N3, M0).  T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  N3: Metastases in ipsilateral infraclavicular (level III) axillary lymph nodes(s) with or without level I, II axillary lymph node involvement; or in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


BRCA-Associated Breast Carcinoma

description: Breast carcinoma caused by deleterious germline mutation in a gene of the BRCA family.


name: Unresectable Hormone Receptor-Positive Breast Carcinoma

description: Hormone receptor-positive breast carcinoma that is not amenable to surgical resection.


name: Invasive Breast Carcinoma of No Special Type with Predominant Intraductal Component

description: An invasive breast carcinoma of no special type characterized by the presence of a predominant ductal carcinoma in situ component and a minor component of invasive carcinoma.


name: Prognostic Stage IA Breast Cancer AJCC v8

description: Stage IA includes: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Pleomorphic lobular carcinoma in situ of breast

description: Breast lobular carcinoma in situ characterized by the presence of neoplastic large cells with marked nuclear pleomorphism.


name: Invasive micropapillary carcinoma of breast

description: An invasive breast carcinoma characterized by the presence of clusters of malignant cells located within artifactual clear stromal spaces that resemble vascular spaces.


name: Anatomic Stage IIIB Breast Cancer AJCC v8

description: Stage IIIB includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Unilateral Breast Carcinoma

description: Breast carcinoma of one breast, or one side of the breast.


Childhood Malignant Breast Neoplasm

description: A malignant neoplasm that affects the breast and occurs during childhood.


Carcinoma in situ of male breast

description: A proliferation of atypical neoplastic epithelial cells confined to the mammary ducts of the male breast. It includes the entire spectrum of carcinoma in situ observed in the female breast. It usually develops in the retroareolar region.


name: Paget's disease and intraductal carcinoma of breast

description: Paget disease of the breast associated with the presence of a usually high grade ductal carcinoma in situ in the lactiferous glands.


Stage III Breast Cancer AJCC v6

description: Stage III is divided into two stages IIIA and IIIB.  Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  Stage IIIB includes: (T4, any N, M0).  T4: Tumor of any size with direct extension to (a) chest wall or (b) skin.  N2: Metastases in ipsilateral axillary lymph nodes fixed or matted, or in clinically apparent ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastasis.  N3: Metastasis in ipsilateral infraclavicular lymph nodes(s) with or without axillary lymph node involvement, or in clinically apparent ipsilateral internal mammary lymph node(s); and in the presence of clinically evident axillary lymph node metastasis or metastasis in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement.  M0: No distant metastasis.  (AJCC 6th Ed.)


Metastatic Breast Lobular Carcinoma

description: A lobular breast carcinoma that has spread from the original site of growth to another anatomic site.


Refractory Breast Adenocarcinoma

description: Breast adenocarcinoma that does not respond to treatment.


name: Invasive Breast Carcinoma by Histologic Grade


Unresectable Breast Carcinoma

description: Breast carcinoma that is not amenable to surgical resection.


name: Recurrent HER2-Negative Breast Carcinoma

description: The reemergence of HER2-negative breast adenocarcinoma after a period of remission.


Breast adenocarcinoma recurrent

description: The reemergence of breast adenocarcinoma after a period of remission.


name: Locally Advanced HER2-Low Breast Carcinoma

description: A HER2-low breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


PALB2-Associated Breast Carcinoma

description: Breast carcinoma caused by deleterious germline mutation in the PALB2 gene.


name: Recurrent Invasive Breast Carcinoma of No Special Type

description: The reemergence of invasive breast carcinoma of no special type after a period of remission.


Metastatic Breast Carcinoma

description: A carcinoma that arises from the breast and has metastasized to another anatomic site.


Refractory Breast Lymphoma

description: Breast lymphoma that is resistant to treatment.


name: Breast Ductal Carcinoma In Situ, Comedo Type

description: Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells with evidence of central necrosis and associated karyorrhectic/nuclear debris.


Occult Breast Carcinoma

description: Breast carcinoma presenting with isolated axillary lymphadenopathy, without clinical or mammographic evidence of breast tumor.


name: Prognostic Stage III Breast Cancer AJCC v8

description: Stage III includes: IIIA: (T0-1, N1, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); IIIB: (T2, N1, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); IIIC: (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any ); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: solid type ductal carcinoma in situ of breast

description: Breast ductal carcinoma in situ in which the tumor cells fill the ductal spaces as solid sheets.


Malignant nipple neoplasm

description: A malignant neoplasm that affects the area of the nipple.


Recurrent Breast Papillary Carcinoma

description: The reemergence of breast papillary carcinoma after a period of remission.


breast liposarcoma

description: A malignant adipose tissue neoplasm of the breast.


name: Prognostic Stage IV Breast Cancer AJCC v8

description: Stage IV includes: Any T, Any N, M1, G1-3, HER2 Status: Any, ER Status: Any, PR Status: Any. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)


name: Metastatic Androgen Receptor-Positive Breast Carcinoma

description: Androgen receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


Breast Carcinoma Metastatic in the Lung

description: A carcinoma that arises from the breast and has metastasized to the lung.


Invasive Breast Apocrine Carcinoma

description: An invasive breast adenocarcinoma with cytological and immunophenotypic characteristics of apocrine differentiation in more than 90 percent of the malignant cells.


name: Anatomic Stage IIIC Breast Cancer AJCC v8

description: Stage IIIC includes: Any T, N3, M0. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Metastatic Triple-Negative Breast Inflammatory Carcinoma

description: Triple-negative breast inflammatory carcinoma that has spread from its original site of growth to another anatomic site.


Carcinoma breast stage I

description: Stage 1 includes T1, NO, MO.  T1: Tumor 2.0 cm or less in greatest dimension.  T1mic: Microinvasion 0.1 cm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th Ed.)-2003


name: Breast Tall Cell Carcinoma with Reversed Polarity

description: A rare subtype of invasive breast carcinoma characterized by tall columnar cells with reversed nuclear polarity, arranged in solid and solid papillary patterns, most commonly associated with IDH2 p.Arg172 hotspot mutations. (WHO 2019)


name: Androgen Receptor-Positive Breast Carcinoma

description: Breast carcinoma that is positive for androgen receptors.


name: Synchronous Ipsilateral Breast Carcinoma

description: Diagnosis of more than one distinct tumor focus in the same breast, within two months.


name: Resectable Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that is amenable to surgical resection.


name: Prognostic Stage IIIC Breast Cancer AJCC v8

description: Stage IIIC includes: (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any ); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T4, N0-2, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (Any T, N3, M0, G3, HER2 Status: Negative, ER Status: Any, PR Status: Any). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Anatomic Stage IIB Breast Cancer AJCC v8

description: Stage IIB includes: (T2, N1, M0); (T3, N0, M0). T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Grade 1 Invasive Breast Carcinoma

description: A well differentiated invasive breast carcinoma.


name: Unresectable HER2-Positive Breast Carcinoma

description: HER2-positive breast carcinoma that is not amenable to surgical resection.


Secondary malignant neoplasm of breast

description: The spread of a malignant neoplasm to the breast. This may be from a primary breast malignant neoplasm on the opposite side, or from a malignant neoplasm at a distant site.


Grade 3 Invasive Breast Carcinoma

description: A poorly differentiated invasive breast carcinoma.


name: Unresectable Estrogen Receptor-Positive Breast Carcinoma

description: Estrogen receptor-positive breast carcinoma that is not amenable to surgical resection.